吴以岭院士微血管病防治项目获国家科技进步一等奖,杨跃进教授为第二位完成人

2020-01-12 佚名 中国循环杂志

在1月10日举行的国家科学技术奖励大会上,由中国工程院院士吴以岭领衔团队完成的“中医脉络学说构建及其指导微血管病变防治”获得国家科学技术进步一等奖,该奖也是年度生命科学领域的唯一一项国家科技进步一等奖。“中医脉络学说构建及其指导微血管病变防治”项目由以岭药业旗下河北以岭医药研究院有限公司为第一完成单位,中国医学科学院阜外医院、江苏省人民医院、武汉大学人民医院、中国人民解放军总医院、复旦大学、中山大

在1月10日举行的国家科学技术奖励大会上,由中国工程院院士吴以岭领衔团队完成的“中医脉络学说构建及其指导微血管病变防治”获得国家科学技术进步一等奖,该奖也是年度生命科学领域的唯一一项国家科技进步一等奖。

“中医脉络学说构建及其指导微血管病变防治”项目由以岭药业旗下河北以岭医药研究院有限公司为第一完成单位,中国医学科学院阜外医院、江苏省人民医院、武汉大学人民医院、中国人民解放军总医院、复旦大学、中山大学、河北医科大学、首都医科大学等共同完成。

实验证实,保护微血管内皮细胞就是治疗临床心脑血管病的关键机制。

中国医学科学院阜外医院杨跃进为第二完成人,该课题组采取了符合国际标准的随机、双盲、多中心、安慰剂平行对照的临床循证医学,证实通心络胶囊治疗急性心梗无再流,能够缩小心梗面积、改善心功能,疗效提高20%,在解决心血管病这一国际难题方面取得重大进展。



杨跃进教授

参松养心胶囊治疗室性早搏伴心功能不全循证研究证实,减少室性早搏的同时改善心功能,为这一临床难题提供新的治疗药物;参松养心胶囊治疗窦性心动过缓伴室性早搏循证研究证实,在减少室早的同时提高心室率,填补了快慢兼治、整合调律药物治疗空白。

芪苈强心胶囊治疗慢性心力衰竭循证研究证实,在西医国际标准化治疗基础上加用芪苈强心胶囊可提高临床疗效16%。

芪苈强心胶囊研究论文发表在国际循环顶尖杂志——《美国心脏病学会杂志》,编辑部评论:让衰竭的心脏更加强劲——中国传统医学给我们的启示。这一研究也被评为该杂志年度学术亮点。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1644822, encodeId=2c7016448223b, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Mon Oct 19 12:04:00 CST 2020, time=2020-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278437, encodeId=233d12e843753, content=<a href='/topic/show?id=0d3f393343e' target=_blank style='color:#2F92EE;'>#吴以岭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39334, encryptionId=0d3f393343e, topicName=吴以岭)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30f5146, createdName=zz70, createdTime=Tue Jan 14 14:04:00 CST 2020, time=2020-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365393, encodeId=ea6613653934c, content=<a href='/topic/show?id=2a2150e76fd' target=_blank style='color:#2F92EE;'>#微血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50776, encryptionId=2a2150e76fd, topicName=微血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Tue Jan 14 14:04:00 CST 2020, time=2020-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1049163, encodeId=ee0110491635d, content=院士是学术至高点,也是大家必争之地呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=junJUN, createdTime=Mon Jan 13 02:04:00 CST 2020, time=2020-01-13, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1644822, encodeId=2c7016448223b, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Mon Oct 19 12:04:00 CST 2020, time=2020-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278437, encodeId=233d12e843753, content=<a href='/topic/show?id=0d3f393343e' target=_blank style='color:#2F92EE;'>#吴以岭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39334, encryptionId=0d3f393343e, topicName=吴以岭)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30f5146, createdName=zz70, createdTime=Tue Jan 14 14:04:00 CST 2020, time=2020-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365393, encodeId=ea6613653934c, content=<a href='/topic/show?id=2a2150e76fd' target=_blank style='color:#2F92EE;'>#微血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50776, encryptionId=2a2150e76fd, topicName=微血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Tue Jan 14 14:04:00 CST 2020, time=2020-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1049163, encodeId=ee0110491635d, content=院士是学术至高点,也是大家必争之地呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=junJUN, createdTime=Mon Jan 13 02:04:00 CST 2020, time=2020-01-13, status=1, ipAttribution=)]
    2020-01-14 zz70
  3. [GetPortalCommentsPageByObjectIdResponse(id=1644822, encodeId=2c7016448223b, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Mon Oct 19 12:04:00 CST 2020, time=2020-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278437, encodeId=233d12e843753, content=<a href='/topic/show?id=0d3f393343e' target=_blank style='color:#2F92EE;'>#吴以岭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39334, encryptionId=0d3f393343e, topicName=吴以岭)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30f5146, createdName=zz70, createdTime=Tue Jan 14 14:04:00 CST 2020, time=2020-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365393, encodeId=ea6613653934c, content=<a href='/topic/show?id=2a2150e76fd' target=_blank style='color:#2F92EE;'>#微血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50776, encryptionId=2a2150e76fd, topicName=微血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Tue Jan 14 14:04:00 CST 2020, time=2020-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1049163, encodeId=ee0110491635d, content=院士是学术至高点,也是大家必争之地呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=junJUN, createdTime=Mon Jan 13 02:04:00 CST 2020, time=2020-01-13, status=1, ipAttribution=)]
    2020-01-14 mgqwxj
  4. [GetPortalCommentsPageByObjectIdResponse(id=1644822, encodeId=2c7016448223b, content=<a href='/topic/show?id=e3eb89e17fb' target=_blank style='color:#2F92EE;'>#血管病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89717, encryptionId=e3eb89e17fb, topicName=血管病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=64bb23195917, createdName=Luyuxie_17, createdTime=Mon Oct 19 12:04:00 CST 2020, time=2020-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278437, encodeId=233d12e843753, content=<a href='/topic/show?id=0d3f393343e' target=_blank style='color:#2F92EE;'>#吴以岭#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39334, encryptionId=0d3f393343e, topicName=吴以岭)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30f5146, createdName=zz70, createdTime=Tue Jan 14 14:04:00 CST 2020, time=2020-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365393, encodeId=ea6613653934c, content=<a href='/topic/show?id=2a2150e76fd' target=_blank style='color:#2F92EE;'>#微血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50776, encryptionId=2a2150e76fd, topicName=微血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Tue Jan 14 14:04:00 CST 2020, time=2020-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1049163, encodeId=ee0110491635d, content=院士是学术至高点,也是大家必争之地呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=junJUN, createdTime=Mon Jan 13 02:04:00 CST 2020, time=2020-01-13, status=1, ipAttribution=)]
    2020-01-13 junJUN

    院士是学术至高点,也是大家必争之地呀

    0